PCM
NGNE icon

Penserra Capital Management’s Neurogene NGNE Stock Holding History

Penserra Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-49
Closed -$7K – 1484
2021
Q3 		$7K Buy
49
+1
+2% +$153 ﹤0.01% 1392
2021
Q2 		$8K Hold
48
– – ﹤0.01% 1287
2021
Q1 		$11K Sell
48
-1
-2% -$256 ﹤0.01% 1025
2020
Q4 		$13K Buy
+49
New +$12K ﹤0.01% 901

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Penserra Capital Management's NGNE Position: Q4 2021 in Review

Penserra Capital Management sold out of Neurogene (NGNE) in Q4 2021, closing a stake of 49 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in NGNE in Q4 2020 and held it in 4 quarters. The position peaked at $13K in Q4 2020. 80 funds tracked by Wall St. Rank hold NGNE as of Q4 2021.

  • Penserra Capital Management reported no remaining Neurogene position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 49 Neurogene shares in Q4 2021, an estimated $7K.
  • Penserra Capital Management first reported a position in Neurogene in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Neurogene position peaked at $13K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Neurogene as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.